CN100347168C - 具有止痛活性的吲唑酰胺类 - Google Patents

具有止痛活性的吲唑酰胺类 Download PDF

Info

Publication number
CN100347168C
CN100347168C CNB2004800025681A CN200480002568A CN100347168C CN 100347168 C CN100347168 C CN 100347168C CN B2004800025681 A CNB2004800025681 A CN B2004800025681A CN 200480002568 A CN200480002568 A CN 200480002568A CN 100347168 C CN100347168 C CN 100347168C
Authority
CN
China
Prior art keywords
methyl
indazole
acid
pharmaceutically acceptable
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800025681A
Other languages
English (en)
Chinese (zh)
Other versions
CN1742004A (zh
Inventor
M·A·阿里希
N·卡佐尔拉
A·古格利尔莫蒂
G·弗尔罗蒂
G·鲁纳
L·普兰扎尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Publication of CN1742004A publication Critical patent/CN1742004A/zh
Application granted granted Critical
Publication of CN100347168C publication Critical patent/CN100347168C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB2004800025681A 2003-02-18 2004-01-26 具有止痛活性的吲唑酰胺类 Expired - Fee Related CN100347168C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000287A ITMI20030287A1 (it) 2003-02-18 2003-02-18 Indazolammidi dotate di attivita' analgesica metodo, per
ITMI2003A000287 2003-02-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2007101801011A Division CN101139341B (zh) 2003-02-18 2004-01-26 具有止痛活性的吲唑酰胺类

Publications (2)

Publication Number Publication Date
CN1742004A CN1742004A (zh) 2006-03-01
CN100347168C true CN100347168C (zh) 2007-11-07

Family

ID=32894157

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2004800025681A Expired - Fee Related CN100347168C (zh) 2003-02-18 2004-01-26 具有止痛活性的吲唑酰胺类
CN2007101801011A Expired - Fee Related CN101139341B (zh) 2003-02-18 2004-01-26 具有止痛活性的吲唑酰胺类

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2007101801011A Expired - Fee Related CN101139341B (zh) 2003-02-18 2004-01-26 具有止痛活性的吲唑酰胺类

Country Status (22)

Country Link
US (2) US7632849B2 (https=)
EP (1) EP1594859B1 (https=)
JP (1) JP4724651B2 (https=)
KR (1) KR101108222B1 (https=)
CN (2) CN100347168C (https=)
AR (1) AR043186A1 (https=)
AT (1) ATE471934T1 (https=)
AU (1) AU2004213104B2 (https=)
CA (1) CA2511984C (https=)
DE (1) DE602004027792D1 (https=)
DK (1) DK1594859T3 (https=)
EA (1) EA009077B1 (https=)
ES (1) ES2345983T3 (https=)
GE (1) GEP20074075B (https=)
IL (1) IL169285A (https=)
IT (1) ITMI20030287A1 (https=)
MX (1) MXPA05008730A (https=)
PL (1) PL215870B1 (https=)
PT (1) PT1594859E (https=)
SI (1) SI1594859T1 (https=)
UA (1) UA79537C2 (https=)
WO (1) WO2004074275A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031468A1 (it) * 2003-07-18 2005-01-19 Acraf Farmaco ativo nel dolore neuropatico
CA2569654C (en) * 2004-06-15 2010-12-21 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US8815892B2 (en) 2008-03-25 2014-08-26 Affectis Pharmaceuticals Ag P2X7R antagonists and their use
BRPI0910034B1 (pt) * 2008-03-25 2022-02-08 Affectis Pharmaceuticals Ag Antagonistas do p2x7r e composições farmacêuticas que os compreendem
AU2010237302A1 (en) * 2009-04-14 2011-12-01 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
BR112014018657B1 (pt) 2012-02-21 2022-08-02 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A Compostos de 1h-indazol-3-carboxamida
AU2013224302B2 (en) 2012-02-21 2017-03-30 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2970177A1 (en) 2013-03-15 2016-01-20 Pfizer Inc. Indole compounds that activate ampk
ES2913975T3 (es) 2018-05-07 2022-06-07 Acraf Compuestos de 1H-indazol-3-carboxamida como inhibidores de la glucógeno sintasa cinasa-3 beta
CN109336890B (zh) * 2018-11-17 2020-03-20 重庆文理学院 一种吲唑类衍生物的合成方法及抗肿瘤应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3705175A (en) * 1969-04-01 1972-12-05 Egyt Gyogyszervegyeszeti Gyar Indazole-3-carboxylic amides
EP0732333A1 (en) * 1995-03-16 1996-09-18 Eli Lilly And Company Indazolecarboxamides
EP0908459A1 (en) * 1997-10-07 1999-04-14 Eli Lilly And Company 5-HT4 Agonists and antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
DE69627323T2 (de) * 1995-05-31 2004-01-15 Nisshin Seifun Group Inc Indazolderivate mit einer cyclischen aminogruppe
AU7507196A (en) * 1995-11-08 1997-05-29 Toray Industries, Inc. Direct drawing type waterless planographic original form plate
JP3911297B2 (ja) 1996-08-16 2007-05-09 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｎ―［（１―ｎブチル―４―ピペリジル）メチル］―３，４―ジヒドロ―２Ｈ―［１，３］オキサジノ［３，２―ａ］インドール―１０―カルボキシアミドおよび塩ならびに製造における中間体
IT1291569B1 (it) 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
US6407103B2 (en) * 1998-04-21 2002-06-18 Bristol-Myers Squibb Pharma Company Indeno [1,2-c] pyrazol-4-ones and their uses
JP4665239B2 (ja) * 1998-04-21 2011-04-06 アゲンニクス アーゲー 抗癌剤および抗増殖性薬剤としての５−アミノインデノ［１，２−ｃ］ピラゾール−４−オン

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3705175A (en) * 1969-04-01 1972-12-05 Egyt Gyogyszervegyeszeti Gyar Indazole-3-carboxylic amides
EP0732333A1 (en) * 1995-03-16 1996-09-18 Eli Lilly And Company Indazolecarboxamides
EP0908459A1 (en) * 1997-10-07 1999-04-14 Eli Lilly And Company 5-HT4 Agonists and antagonists

Also Published As

Publication number Publication date
AR043186A1 (es) 2005-07-20
CN101139341A (zh) 2008-03-12
WO2004074275A1 (en) 2004-09-02
EA009077B1 (ru) 2007-10-26
HK1079199A1 (en) 2006-03-31
EP1594859A1 (en) 2005-11-16
GEP20074075B (en) 2007-03-26
US20100048907A1 (en) 2010-02-25
EP1594859B1 (en) 2010-06-23
US20060052417A1 (en) 2006-03-09
CA2511984A1 (en) 2004-09-02
IL169285A (en) 2012-08-30
JP4724651B2 (ja) 2011-07-13
PL377236A1 (pl) 2006-01-23
KR20050101541A (ko) 2005-10-24
AU2004213104A1 (en) 2004-09-02
UA79537C2 (en) 2007-06-25
CN101139341B (zh) 2010-12-08
DE602004027792D1 (de) 2010-08-05
KR101108222B1 (ko) 2012-02-08
US8519139B2 (en) 2013-08-27
EA200501164A1 (ru) 2005-12-29
SI1594859T1 (sl) 2010-10-29
US7632849B2 (en) 2009-12-15
ES2345983T3 (es) 2010-10-07
CA2511984C (en) 2011-01-18
ATE471934T1 (de) 2010-07-15
DK1594859T3 (da) 2010-10-11
MXPA05008730A (es) 2005-09-20
JP2006517932A (ja) 2006-08-03
ITMI20030287A1 (it) 2004-08-19
PL215870B1 (pl) 2014-02-28
CN1742004A (zh) 2006-03-01
PT1594859E (pt) 2010-07-23
AU2004213104B2 (en) 2010-07-08

Similar Documents

Publication Publication Date Title
CN1231478C (zh) 光学活性的哌啶中间体的制备方法和该中间体
CN1273451C (zh) 哌啶mch拮抗剂及其治疗肥胖症的用途
CN1083431C (zh) 新的杂环化合物
CN1163484C (zh) 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
EP1527048B1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
CN1133593A (zh) 用于治疗的哌嗪化合物
CN1636980A (zh) 二肽腈组织蛋白酶k抑制剂
CN1047385C (zh) 3-吲哚基哌啶和含有它们的药物组合物
CN1950323A (zh) Crth2受体拮抗剂
CN101031548A (zh) N－(4－氟苄基)－n－(1－甲基哌啶－4－基)－n'－(4－(2－甲基丙氧基)－苯基甲基)脲的盐及其制备
CN1882541A (zh) N－[苯基(烷基－2－哌啶基)甲基]苯甲酰胺衍生物,其制备和治疗用途
CN1845921A (zh) 金刚烷和氮杂双环－辛烷及壬烷衍生物、其制备方法及其作为dpp－iv抑制剂的用途
CN100347168C (zh) 具有止痛活性的吲唑酰胺类
CN1812963A (zh) 用于治疗阿尔茨海默病的N－烷基苯基甲酰胺β分泌酶抑制剂
CN1287487A (zh) 氨基苯氧基乙酸衍生物和含有它们的药用组合物
CN1349524A (zh) 血管紧张肽原酶抑制剂
CN1922162A (zh) 烷基哌嗪－和烷基高哌嗪－羧酸酯衍生物、其制备方法及其作为faah酶抑制剂的用途
CN1438897A (zh) 焦虑性神经症或抑郁症治疗剂,及哌嗪衍生物
CN1922138A (zh) 芳氧基烷基氨基甲酸酯类衍生物,它们的制备方法与治疗用途
CN1113059C (zh) 用作神经激肽拮抗剂的哌嗪并衍生物
CN1041088C (zh) 光学活性咪唑烷酮衍生物和抗痴呆药物组合物
CN1301991C (zh) 哌啶衍生物、其制备方法、以及含有该衍生物的用于治疗阿耳茨海默氏病的药物组合物
CN1777597A (zh) 具有止痛活性的吲唑
CN1729160A (zh) 治疗慢性痛的药物
CN1227230C (zh) Nmda受体配体的前药

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071107

Termination date: 20180126